written on 17.06.2014

Analyst: GlaxoSmithKline's Tykerb dead in the water after breast cancer failure


GlaxoSmithKline's cancer treatment Tykerb took a blow last month when it failed a major late-stage trial in breast cancer. Now, at least one analyst figures the drug is crippled by that data–and that marketing it for breast cancer would be a waste of money.